Squamous cell carcinoma antigens SCCA1 and SCCA2 are highly homologous serine proteinase inhibitors which have been widely utilized as serological markers for squamous cell cancers, but it has recently been demonstrated that only SCCA2 is truly specific for certain forms of lung cancer. Using a construct containing the 5 0 -flanking region of the SCCA2 gene between À460 and þ 0 bp and the luciferase reporter gene, SCCA2 promoter activity was detected in SCCA2-producing SCC cell lines (LK-2, LC-1), but not in SCCA2-nonproducing lung adenocarcinoma cell lines (A549, ABC-1, and RERF-LC-MS) or normal cells (WI-38, SAEC, and NHEKAdult). Infection with a recombinant adenovirus vector, Ad-SCCA2-DsRed, resulted in cell-specific expression of the SCCA2 promoter-driven DsRed marker gene only in LK-2 and LC-1 cells. The same strategy was used for SCCA2-driven expression of a proapoptotic gene, (KLAKLAK)2, which can cause mitochondrial disruption by triggering mitochondrial permeabilization and swelling, resulting in the release of cytochrome c and induction of apoptosis. Infection with Ad-SCCA2-KLAKLAK2 specifically reduced the growth of the two human lung SCC cell lines compared to the SCCA2 nonproducing cell lines both in vitro and in vivo, suggesting that the SCCA2 promoter had a tumor-specific effect. These results suggest that transduction of SCCA2 promotercontrolled suicide genes by adenoviral vectors can confer transcriptionally targeted cytotoxicity in SCCA2-producing lung SCC cells, and represents a novel strategy for gene transfer specifically targeted to SCC in the lung. 
Introduction
Lung carcinoma is the most common malignant neoplasm and represents the leading cause of cancer death in the developed world. 1 Among lung carcinomas, adenocarcinoma and squamous cell carcinoma (SCC) are the most frequently encountered forms. Despite the use of optimal chemotherapy and radiotherapy regimens, there has been little improvement in the prognosis of these cancer patients during the last decade. 2, 3 This underscores the need to seek novel therapeutic modalities for lung cancer patients. One such approach is gene therapy by administration of vectors expressing cytotoxic genes; however, in order to maximize tumor-killing efficacy and minimize any potential adverse effects of this approach, it would be advantageous to employ a cancer-specific targeting strategy. For adenocarcinomas in general, transcriptional targeting by the use of cancer-specific promoters such as the carcinoembryonic antigen (CEA) promoter has been described previously. 4, 5 However, little has been reported for SCC-specific regulation.
The squamous cell carcinoma antigen (SCCA) was first reported by Kato et al. 6 in 1977 as a circulating tumor marker for SCC, particularly that of cervix, head and neck, esophagus, and lung. 7 Several studies have shown that increased serum SCCA levels are seen in SCC patients 8, 9 and correlate with the extent of disease in patients with SCC, 10, 11 although the protein itself is not detected in adenocarcinomas. 6 In a previous study, it was reported that this tumor marker could be separated into two fractions (a neutral form and an acidic form).
genome has revealed the presence of two tandem arrayed genes, SCCA1 and SCCA2, that are 95% identical in cDNA nucleotide sequence. Interestingly, although their amino-acid sequences also indicate that SCCA1 and SCCA2 share 92% identical residues overall with predicted identical secondary structures, 13 structural and functional analyses of the recombinant proteins show that SCCA1 encodes a papain-like cysteine proteinase inhibitor comprising the neutral SCCA fractions, whereas SCCA2 encodes a chymotrypsin-like serine proteinase inhibitor comprising the acidic fractions. 13, 14 Non-cancerous squamous epithelia mostly expresses the neutral fraction encoded by the SCCA1 gene, whereas SCC tissues contain both acidic and neutral SCCA fractions. 15 Quantitative analyses have also shown that SCCA1 mRNA did not show significant differences between SCC and normal tissues, 14 while high expression of SCCA2 mRNA was seen in SCC tissues but not in normal tissues 14 and was associated with a poor prognosis in SCC of the head and neck. 16 Acidic SCCA (SCCA2) has been proposed to protect the epithelial barrier against cathepsin G and human mast cell chymase-induced inflammation and tissue degradation, 17 so that an increase in SCCA2 expression in malignant squamous cells might serve to protect against host inflammatory responses.
Cell type-specific expression of the SCCA2 gene might be conveyed by its promoter region. The complete SCCA2 gene locus has been cloned and its putative promoter region analyzed. The putative SCCA2 promoter region, which contains about 450 nucleotides upstream from the translational start site, exhibited a higher promoter activity in SKGIIIa (producing SCCA2) than in nonproducing SK-OV-3 or K42. 18, 19 Interestingly, at nucleotide position À50, the A residue in SCCA2 is replaced by a G residue in SCCA1, and this appears to be responsible for the difference in transcriptional activities of the SCCA1 and SCCA2 core promoters. 19 To determine whether the SCCA2 promoter could be used to target lung SCC, we constructed and tested adenoviral vectors expressing a proapoptotic gene, (KLAKLAK)2, 20 under the control of the SCCA2 promoter. Previous work has suggested that internalized antimicrobial peptides, (KLAKLAK)2, can cause mitochondrial disruption by triggering mitochondrial permeabilization and swelling, resulting in the release of cytochrome c and induction of apoptosis. [20] [21] [22] In this study, we examined the tumor-specific suppression of SCCA2 promoter/proapoptotic gene on progression of a human lung SCC tumor, LC-1, in nude mice. These results suggest that gene therapy for SCC of the lung might be possible under the appropriate cell type-specific promoter.
Materials and methods

Cell lines and culture conditions
Human lung SCC cell lines LC-1 and LK-2, and adenocarcinoma cell lines A549, ABC-1, and RERF-LC-MS were obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan). These lung cancer cell lines were maintained in RPMI-1640 medium (SigmaAldrich Co. Ltd, Irvine, CA) supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, and 1% penicillin/streptomycin (p/s). WI-38 human lung fibroblasts were obtained from the RIKEN Cell Bank (Tsukuba, Japan), and were grown in Dulbecco's modified Eagle's medium (D-MEM, Sigma-Aldrich) with 10% FBS and 1% p/s. Primary human small airway epithelial cells (SAEC) and adult normal human epidermal keratinocytes (NHEK-Adult) were purchased from the Clonetics Corporation (San Diego, CA). Primary human small airway epithelial cells were grown in bronchial epithelial cell growth medium (BEGM, Clonetics) as previously described. 23 NHEK-Adult were grown in serum-free keratinocyte growth medium (KGM, Clonetics). All cells were maintained in a humidified incubator with 5% CO 2 in atmosphere in air at 371C.
Plasmids
The nucleotide sequence data for the SCCA2 genes was reported in the DDBJ/EMBL/GenBank nucleotide sequences with accession number AB035089. Genomic DNA was purified from 293 cells using Sepa Gene (Sanko Junyaku, Tokyo, Japan). The core SCCA2 promoter upstream from the exon 1 of SCCA2 (between À460 and þ 0) was PCR-amplified from the genomic DNA with amplifying primer pair adding KpnI/XhoIrecognizing sequence (sense primer, 5 0 -TACGGGTACC TAGGATGACAAAAACTTTCAG-3 0 ; antisense primer, 5 0 -CTATCTCGAGGGGTGAGATCCTAAATTTAT-3 0 ). The 480 bp KpnI/XhoI fragment containing the core SCCA2 promoter was digested and inserted into the upstream of the luciferase gene in vector pGL3-Basic (Promega, Madison, WI) to make pGL3-SCCA2. The red fluorescent protein (DsRed) gene was obtained by PCR on the vector pDsRed1-N1 (Clontech, Tokyo, Japan) with the primers adding HindIII/XbaI-recognizing sequence (sense primer, 5 0 -GGGGGAAGCTTAGTAC TATGGTGCGCTCCTCCAAG-3 0 ; antisense primer, 5 0 -GGGGGTCTAGACTACAGGAACAGGTGGTGGC-3 0 ). To generate the pGL3-SCCA2-DsRed, the DsRed fragment was digested with HindIII and XbaI, and was replaced into pGL3-SCCA2 digested with the same enzymes. The oligonucleotides of the proapoptotic gene, (KLAKLAK)2, was synthesized by adding NcoI/XbaIrecognizing sequence(ccatggATGGGAGGAAAACTTG CTAAGCTCGCTAAAAAGCTAGCTAAACTGGCTA AGCATCATCATCATCATCATTAAtctaga) and inserted into the frame right of the SCCA2 promoter sequence. After digesting with NcoI and XbaI, the (KLAKLAK)2 fragment was replaced into pGL3-SCCA2 digested with the same enzymes. The resulting plasmid was named pGL3-SCCA2-KLAKLAK2. The sequencing reactions were carried out using a DNA sequencing kit (Perkin-Elmer, Foster City, CA) as suggested by the manufacturer and were analyzed using an ABI PRISM 310 Genetic Analyzer (Perkin-Elmer).
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Recombinant adenovirus vectors
Recombinant adenovirus vectors were generated by a simplified system using homologous recombination in bacteria 24 (generously provided by B Vogelstein, Johns Hopkins, Baltimore, MD). Briefly, the NotI/SalI fragment of pGL3-SCCA2-DSRed and pGL3-SCCA2-KLAKLAK2 were cloned respectively into shuttle vectors, pAdTrack which contains cytomegalovirus (CMV) promoter-driven green fluorescent protein (GFP) coding sequence. 24 Simple pAdTrack and the resulting recombinant adenovirus plasmids, pAd-SCCA2-DsRed and pAd-SCCA2-KLAKLAK2 were constructed by co-transformation with the backbone plasmid pAdEasy-1, into the recombinogenic Escherichia coli strain BJ5183 to generate replication-deficient adenoviruses, viral vector control (Ad-CMV-GFP), Ad-SCCA2-DsRed, and Ad-SCCA2-KLAKLAK2, respectively ( Figure 1 ). Each recombinant adenovirus was expanded in the 293 cells and was purified by banding in cesium chloride and dialysis for 8 h at 41C with two changes of phosphatebuffered saline (PBS) containing 10% glycerol. The viral titers were determined by plaque-forming activity in 293 cells. 25 To evaluate the transduction efficiency of the recombinant adenovirus into each cell lines, GFP activity was evaluated by using a recombinant Ad-CMV-GFP to achieve 100% transduction.
Adenoviral transduction efficiency
FACScan (Becton Dickinson, San Jose, CA) was used to determine reference titers on lung cancer cell lines by fluorescence-activated cell sorter (FACS) analysis for GFP expression. Transduction was performed with viral vector stocks at a MOI of 50, 100, 400, 600, 800, and 1000. The actual cell number at the time of infection was determined by trypsinizing and counting uninfected wells that had been plated in parallel. The cells were collected 48 h after infection, and the number of GFP-positive cells within the linear range of FACScan detection was used to quantify the titer.
Detection of SCCA1 and SCCA2 mRNA expression by RT-PCR To examine SCCA1 and SCCA2 mRNA expression in lung cancer cells, airway epithelial cells, lung fibroblasts, and keratinocytes, RT-PCR was performed. Total RNA was isolated with TRIZOL Reagent (GIBCO) from each cell lines. A measure of 1 mg of each RNA preparation was then used as a template to synthesize cDNA. To detect cDNA encoding SCCA1 expressed as a 239 bp band or SCCA2 expressed as a 696 bp band, 2 ml of each cDNA preparation was amplified by PCR using 10 pmol each of forward and reverse primers specific for SCCA1 (sense primer, 5 0 -AGACACACATAGCCTCTCTG-3 0 ; antisense primer, 5 0 -CTTCTTAATCTGTTGTGCAGT GTT-3 0 ) or SCCA2 (sense primer, 5 0 -TTCATTCCACA GACACACACAG-3 0 ; antisense primer, 5 0 -CTTGTT TGGCCAAAATTTTTCC-3 0 ), respectively. Amplification conditions were 941C for 30 s, 541C for 30 s and 721C for 1 min for 35 cycles at SCCA1 mRNA detection or 941C for 1 min, 521C for 30 s and 721C for 30 s for 35 cycles at SCCA2 mRNA detection. Beta-actin was used as an internal control standard. The PCR products were electrophoresed in a 1% agarose gel and visualized by ethidium bromide staining.
SCCA2 promoter activities of various cell lines
The SCCA2 promoter activities on each cell line were evaluated by luciferase assay. The pGL3-SCCA2 and pGL3-basic vector, which was used as internal control, and the pGL3-promoter vector, which was the PGL3-control vector with SV40 upstream of luciferase and used for positive control were used for this study (Promega). For transient luciferase assays, cells were transfected using a lipid-DNA complex containing 12 ml of lipofectamine reagent (GIBCO) and 3 mg of pGL3-basic, pGL3-SCCA2 or pGL3-promoter. Eighteen hours after the addition of the DNA-lipofectamine reagent complexes, the medium was changed. The cells were incubated for 48 h, and then cell extracts were prepared using Reporter Lysis Buffer (Promega). Luciferase assays were performed 
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Ad-SCCA2-DsRed infection to various cell lines
To examine CMV promoter-driven GFP and SCCA2 promoter-driven DsRed expression in the Ad-SCCA2-DsRed infected cells, fluorescence microscopy work and RT-PCR were performed. The cells were infected with Ad-SCCA2-DsRed at a MOI that gave 80-90% transduction efficiency and observed using fluorescence microscopy (OLYMPUS IX50, Olympus, Tokyo, Japan). Next, RT-PCR was performed using total RNA isolated from infected cells with primer pair specific to GFP or DsRed cDNA. These primer sets can detect cDNA encoding DsRed or GFP expressed as a709 bp or a803 bands, respectively. Amplification conditions were 941C for 15 s, 581C for 15 s and 721C for 2 min for 30 cycles.
Proliferation assay
To examine the growth rate of cells, colorimetric proliferation assay was performed. Briefly, 1 Â 10 5 cells in 100 ml of culture medium per well were seeded into 96-well, flat-bottomed plates. Cells were infected with Ad-CMV-GFP or either of the Ad-SCCA2 constructs (Ad-SCCA2-DsRed or Ad-SCCA2-KLAKLAK2) at a MOI of 800 (LC-1, LK-2, and ABC-1), or 400 (A549 and RERF-LC-MS), or 100 (SAEC, WI-38, and NHEKAdult). Following incubation for 72 h, 10 ml of 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-8; Dojindo, Kumamoto, Japan) were added to each well. After 2 h of incubation, the optical density was read on a microplate autoreader (SPECTRAmax s 190; Molecular Devices Corp., Sunnyvale, CA) using a test wavelength of 490 nm and a reference wavelength of 620 nm. Each experiment was carried out in triplicate.
Detection of apoptotic cells in vitro
Confirmation of SCC death by apoptosis after infection of Ad-SCCA2-KLAKLAK2 was performed by using fluorescent DNA-binding dye, Hoechst 33258. LC-1 and NHEAK-Adult infected with Ad-CMV-GFP or Ad-SCCA2-KLAKLAK2 were fixed with 4% paraformaldehyde for 20 min at room temperature. After washing in distilled water, they were incubated in Hoechst 33258 (10 mg/ml) for 5 min. Nuclear morphology was examined by fluorescence microscopy. Apoptotic cells were counted in three independent fields.
In vivo experiments
Male athymic BALB/c nude mice aged 6 weeks, were purchased from Charles River Japan, Kanagawa, Japan. All the mice were maintained under specific pathogen-free conditions according to the institute's guidelines for care and use of experimental animals. Subcutaneous inoculation of 1.5 Â 10 6 LC-1 or A549 cells in 0.1 ml medium was performed on day 0. Seven days later, when the tumor diameter reached 5-7 mm, the tumors were infected with Ad-SCCA2-DsRed, Ad-SCCA2-KLAKLAK2 (LC-1;1.2 Â 10 9 PFU/100 ml, A549; 0.6 Â 10 9 PFU/100 ml) or PBS (100 ml). The 100 ml volume was distributed throughout the mass or around the edge of the tumor evenly.
To confirm how many cells were infected and how many of them were SCCA2 promoter-positive in the tumors infected with Ad-SCCA2-DsRed, immunohistochemistry using anti GFP or DsRed antibody was performed. Tumor volumes were estimated by the following formula: volume ¼ (a Â b 2 )/2, where a is the longest diameter and b is the smallest diameter. 26 Mice were sacrificed 27 days later as per the experimental protocol. Tumors were fixed in PBS containing 10% formaldehyde and stained for TUNEL (Apoptosis in situ Detection Kit, Wako, Tokyo, Japan) and counterstained with methyl green.
Statistical analysis
The results are presented as mean7standard error of the mean. Statistical analysis of the differences between the mean was calculated using Student's t-test, and a P-value o0.05 was taken to indicate statistical significance.
Results
Optimal multiplicity of infection (MOI) for viral transduction in each cell lines
In A549 and RERF-LC-MS, 80% of the infected cells were GFP positive at a MOI of 400. In contrast, transduction efficiency of the SCC cell lines and ABC-1 was 80% at a MOI of 800. For WI-38, NHEK-Adult and SAEC, the optimal MOI was 100 to get 90% transduction efficiency. These MOI were used to infect cells in all subsequent in vitro experiments. Toxicity was not observed at MOIo1000.
Squamous cell cancer-specific transcription of the endogenous SCCA2 gene
The human lung SCC cell lines LC-1 and LK-2, the adenocarcinoma cell lines A549, ABC-1, and RERF-LC-MS, and the normal cell lines WI-38, SAEC, and NHEKAdult were examined for expression of SCCA1 and SCCA2 mRNA by RT-PCR ( Figure 1a) . As expected, the 239 bp SCCA1 RT-PCR product was readily detected in all cell lines, except for the normal human lung fibroblast cell line WI-38. However, the 696 bp SCCA2 fragment was confirmed to be present only in the SCC cell lines, LC-1 and LK2. In contrast, none of the other cell lines tested showed detectable levels of SCCA2 mRNA signal.
Cell type-specific activity of SCCA2 promoter The luciferase reporter assay was employed to quantify the activity of the SCCA2 promoter sequence to be employed for SCC-specific transgene expression (Figure 1b) . In the two SCC cell lines (LC-1 and LK-2) that express the endogenous SCCA2 gene, high levels of SCCA2 promoter-driven luciferase activity was observed, measuring 46 and 58%, respectively, that of cells transfected with the SV40-driven positive control. Low SCCA2 promoter for selective apoptosis induction T Oshikiri et al background levels of SCCA2 promoter activity were seen in the non-SCC cell lines A549, ABC-1, RERF-LC-MS, WI-38, SAEC, and NHEK-Adult, ranging between 1-10% that of the positive control. There was significant difference between the two groups (Po0.05). Thus, the SCCA2 promoter was found to be capable of directing efficient SCC-selective transgene expression.
Cell type-specific expression of DsRed gene We first constructed and tested the cell specificity of an E1, E3-deleted adenovirus vector, Ad-SCCA2-DsRed, which contains dual reporter gene cassettes consisting of a CMV-driven GFP marker gene and a SCCA2 promoterdriven DsRed marker gene (Figure 2a) . To confirm that DsRed was expressed specifically in those cell lines that had shown high luciferase activities in transient transfection experiments, marker gene fluorescence and mRNA expression were evaluated after adenoviral transduction. As expected, CMV promoter-driven green fluorescence and the 803 bp GFP RT-PCR product were observed in all cell lines after infection by Ad-SCCA2-DsRed. In contrast, red fluorescence and the 709 bp DsRed RT-PCR product were detected only in the SCC cell lines LC-1 and LK2 (Figure 2b and c) , confirming the fidelity of SCCA2 promoter-driven transgene expression in the context of the adenovirus vector. There was no evidence of promoter interference from the CMV-GFP cassette, which is situated downstream from the polyadenylation signal of the SCCA2-DsRed cassette.
Effect of Ad-SCCA2-KLAKLAK2 on cell growth in vitro We next constructed and produced an E1, E3-deleted adenovirus vector, Ad-SCCA2-KLAKLAK2, expressing the proapoptotic peptide KLAKLAK2 under the control of the SCCA2 promoter, and examined its antiproliferative effects on SCC cell lines in vitro (Figure 3a ). Significant suppression of cellular growth was observed 72 h after infection with Ad-SCCA2-KLAKLAK2 only in the SCC cell lines LC-1 and LK2, to 62.1% (Po0.05) and 63.4% (Po0.05) that of uninfected cells, respectively. On the other hand, cell growth was not affected in non-SCC cell lines after infection with Ad-SCCA2-KLAKLAK2.
Hoechst 33258 staining for apoptosis detection Chromatin morphology was analyzed by nuclear staining with Hoechst 33258 (Figure 3b) . In SCCA2-positive LC-1cells, infection with the negative control vector Ad-CMV-GFP showed homogeneous nuclear staining with no change in nuclear shape (Figure 3b, panel a) , while considerable condensation of nuclear chromatin and nuclear fragmentation occurred in Ad-SCCA2-KLAK-LAK2 infected cells (Figure 3b, panel b) . In contrast, non-SCC cell lines such as NHEK-Adult cells showed no differences in cell morphology 72 h after incubation with either Ad-SCCA2-KLAKLAK2 or the negative control vector Ad-CMV-GFP (Figure 3b, panel c, d ). 
Discussion
In the present study, we have demonstrated the therapeutic potential of utilizing the SCCA2 core promoter for SCC-specific transgene expression in the context of a conventional adenovirus vector. Indeed, Ad-SCCA2-KLAKLAK2 infection specifically reduced the growth of human lung SCC cell lines compared with non-SCC cell lines in vitro and in vivo, without evidence of vectorrelated toxicity, suggesting that the SCCA2 promoterdriven was capable of achieving stringent cell type-specific regulation of apoptosis, a sensitive process that can easily be triggered if background levels of proapoptotic gene expression are sufficiently leaky. As regards the discrepancy of the growth inhibition rate between the in vitro and in vivo, it may be attributed to the bystander effect in vivo. In vitro, natural apoptosis occurs in all models after 72 h. But in vivo, diffusion of virus for bystander tumor cells may occur. We will inspect this theme in the future.
It is notable that, while the promoter sequences of SCCA1 and SCCA2 are quite similar, the use of the SCCA2 promoter to achieve SCC-specific transgene expression is supported by the following lines of evidence. First, the transcriptional activity of the SCCA2 promoter After subcutaneous inoculation of 1.5 Â 10 6 LC-1 (SCC) or A549 (adenocarcinoma) cells in nude mice, each indicated adenovirus (1.2 Â 10 9 PFU/100 ml or 0.6 Â 10 9 PFU/100 ml) or PBS vehicle was injected intratumorally (Day 7, arrows). Tumor volumes were measured as described in Materials and methods. Values shown are mean7s.e. (n ¼ 4). *Po0.05. Tumor volumes of LC-1 squamous cell carcinomas were significantly reduced following treatment with Ad-SCCA2-KLAKLAK2 compared to Ad-SCCA2-DsRed treatment.
in normal cell lines was extremely low. In contrast, although we did not specifically examine the transcriptional activity of the SCCA1 promoter, SCCA1 mRNA has previously been detected not only in SCC cell lines but also in normal cell lines, including SAEC and NHEKAdult cells. Hamada et al. 19 also reported that the transcriptional activity of the SCCA1 promoter was higher than that of the SCCA2 promoter in normal cell lines. In addition, this low level of background activity in non-SCC cells was also presumably advantageous for generating and expanding Ad-SCCA2-KLAKLAK2 in 293 human embryonic kidney cells, that is, as SCCA2 promoter activity in 293 cells is extremely low (data not shown), the adenovirus vector did not express KLAK-LAK2 and apoptosis was not prematurely induced in the 293 cells during virus production. Finally, expression of endogenous SCCA2 as well as transgenes driven by the SCCA2 core promoter appears to be specific for squamous cell-derived malignancies.
Cancer cell specificity is an important factor in the application of gene therapy against cancer. Systemic delivery of therapeutic genes has the potential to induce serious side effects. Previously, for example, it has been shown that systemic administration of adenovirus vectors expressing the Bax gene suppressed tumor growth in vivo but also resulted in massive apoptosis in the liver. 27 Although systemic delivery was not attempted in the present studies, the present results suggest that transcriptional targeting through the use of SCCA2 promoter may prove useful in reducing the potential for adverse side effects in normal tissues and in enhancing the therapeutic effect in SCC tumors. To prove the safety certainly, the systemic injection of the vectors into mice and the analyses of major organs will be necessary and subject in future. The toxicity and histological analyses of the lung will be especially important.
In particular, it may be useful to employ this strategy for transcriptional targeting in combination with methods for physical targeting of adenoviral vectors to tumor cells, as well as to control proliferation and oncolysis of replication-competent adenoviral vectors.
